Form 4: Replimune Group Director Sells Shares to Cover Tax Obligations

Director Philip Astley-Sparke sold 32,279 shares of Replimune Group, Inc. to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• Philip Astley-Sparke, a director of Replimune Group, Inc., sold 32,279 shares of common stock on May 20, 2025.
• The sale was executed to cover tax withholding obligations associated with the partial vesting of the director's restricted stock units (RSUs).
• The shares were sold at a weighted average price of $8.06, with individual transactions ranging from $8.05 to $8.80 per share.
• Following the transaction, Astley-Sparke still beneficially owns 1,405,071 shares of Replimune Group, Inc.
• The sale was conducted according to an irrevocable 'sell to cover' provision in the RSU award agreements, indicating it was not a discretionary sale.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations and doesn't necessarily reflect the director's view on the company's prospects.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and directors. This transaction is not necessarily indicative of the director's sentiment towards the company's future prospects.

Comparison to Industry Standards

• It is common for executives and directors in publicly traded companies, including those in the biotechnology sector like Replimune, to utilize 'sell to cover' provisions to manage tax liabilities associated with equity compensation.
• Comparable companies such as Amgen, Gilead Sciences, and Biogen also see similar transactions reported via Form 4 filings.
• The volume of shares sold and the price range are within typical parameters for such transactions, and do not raise immediate concerns when compared to industry benchmarks.

Stakeholder Impact

• The sale of shares could have a minor, temporary impact on the stock price due to the increased supply.
• However, since it's a pre-planned transaction to cover tax obligations, the impact is likely to be minimal.

Key Dates

Keywords

Replimune Group, Director Share Sale, Form 4, Astley-Sparke, Tax Withholding, Restricted Stock Units, REPL